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ARTICLE
Zebrafish behavioural profiling identifies GABA and
serotonin receptor ligands related to sedation and
paradoxical excitation
Matthew N. McCarroll1,11, Leo Gendelev1,11, Reid Kinser1, Jack Taylor 1, Giancarlo Bruni 2,3,
Douglas Myers-Turnbull 1, Cole Helsell1, Amanda Carbajal4, Capria Rinaldi1, Hye Jin Kang5, Jung Ho Gong6,
Jason K. Sello6, Susumu Tomita7, Randall T. Peterson2,10, Michael J. Keiser 1,8 & David Kokel1,9
Anesthetics are generally associated with sedation, but some anesthetics can also increase
brain and motor activity—a phenomenon known as paradoxical excitation. Previous studies
have identified GABAA receptors as the primary targets of most anesthetic drugs, but how
these compounds produce paradoxical excitation is poorly understood. To identify and
understand such compounds, we applied a behavior-based drug profiling approach. Here, we
show that a subset of central nervous system depressants cause paradoxical excitation in
zebrafish. Using this behavior as a readout, we screened thousands of compounds and
identified dozens of hits that caused paradoxical excitation. Many hit compounds modulated
human GABAA receptors, while others appeared to modulate different neuronal targets,
including the human serotonin-6 receptor. Ligands at these receptors generally decreased
neuronal activity, but paradoxically increased activity in the caudal hindbrain. Together, these
studies identify ligands, targets, and neurons affecting sedation and paradoxical excitation
in vivo in zebrafish.
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Anesthetics and other central nervous system (CNS)depressants primarily suppress neural activity, butsometimes they also cause paradoxical excitation1. During
paradoxical excitation, brain activity increases2,3 and produces
clinical features such as confusion, anxiety, aggression, suicidal
behavior, seizures, and aggravated rage4,5. These symptoms pri-
marily affect small but vulnerable patient populations including
psychiatric, pediatric, and elderly patients6,7. Understanding
paradoxical excitation is important for discovering, under-
standing, and developing CNS depressants and for understanding
how small molecules affect the vertebrate nervous system. How-
ever, relatively few compounds have been identified that cause
paradoxical excitation, and few model systems have been iden-
tified that reproducibly model paradoxical excitation in vivo.
Many ligands that cause paradoxical excitation are agonists or
positive allosteric modulators (PAMs) of GABAA receptors
(GABAARs), the major type of inhibitory receptors in the CNS8.
However, it is likely that other mechanisms also affect paradoxical
excitation. One such mechanism may involve serotonin imbal-
ance, which affects behavioral disinhibition9,10, and has para-
doxical effects on neuronal circuit output11. For example, the
serotonin-6 receptor (HTR6) is an excitatory G protein-coupled
receptor (GPCR) reported to modulate cholinergic and gluta-
matergic systems by disinhibiting GABAergic neurons12. In ser-
otonin syndrome, excessive serotonergic signaling causes
agitation, convulsions, and muscle rigidity. Despite these excita-
tory effects of excessive serotonergic signaling, several serotonin
receptor agonists are used as anxiolytics, hypnotics, and antic-
onvulsants13. Examples include clemizole and fenfluramine,
which promote 5-HT signaling and have anticonvulsant proper-
ties in humans and zebrafish13,14. By contrast, serotonin
antagonists and inverse agonists improve sleep and are used for
treating insomnia15. Furthermore, serotonin receptors are sec-
ondary and tertiary targets of some anesthetics, suggesting that 5-
HT receptors may contribute to sedation16. However, the
potential impact of serotonin receptors on anesthesia and para-
doxical excitation is poorly understood.
In principle, large-scale behavior-based chemical screens would
be a powerful way to identify compounds that cause sedation and
paradoxical excitation. The reason is that phenotype-based
screens are not restricted to predefined target-based assays.
Rather, phenotype-based screens can be used to identify targets
and pathways that produce poorly understood phenotypes.
Indeed, virtually all CNS and anesthetic drug prototypes were
originally discovered based on their behavioral effects before their
targets were known17. Furthermore, these compounds were
valuable tools for understanding the mechanisms of anesthesia
and sedation. Although behavior-based chemical screens in ver-
tebrates would be most relevant for human biology, behavioral
assays in mice, primates, and other mammals are difficult to scale.
Zebrafish are uniquely well-suited for studying the chemical
biology of sedation and paradoxical excitation. Zebrafish are
vertebrate animals with complex brains and behaviors, they are
small enough to fit in 96-well plates, and they readily absorb
compounds dissolved in the fish water. Compared with humans,
zebrafish share many conserved genes and neurotransmitter sig-
naling pathways18. For example, the zebrafish genome contains
orthologs for all but two human GABAAR subunit isoforms19.
The α-isoform family is the largest and most diverse family of
GABAAR subunits in both humans and zebrafish20. The zebrafish
genome also encodes orthologs of serotonin receptors, including
orthologs of HTR621,22. Additionally, there are several important
differences between the species. One such difference is that the
zebrafish genome encodes a GABAAR β4-subunit, which does not
have a clear ortholog in mammals19. Another difference is that
whereas mammals have six GABAAR α-subunit isoforms,
zebrafish have eight20. Previously, drug profiling studies in zeb-
rafish have identified neuroactive compounds related to anti-
psychotics, fear, sleep, and learning23–26. However, specific
behavioral profiles for compounds that cause paradoxical exci-
tation have not been previously described in zebrafish.
The purpose of these studies is to identify and understand
compounds that cause paradoxical excitation. First, we develop a
scalable model of paradoxical excitation in zebrafish. Then, we
use this model in large-scale chemical screens to identify dozens
of compounds that cause paradoxical excitation. Third, we use
these compounds as research tools to identify receptors affecting
sedation and paradoxical excitation. Finally, we map whole-brain
activity patterns during these behavioral states. Together, these
studies improve our understanding of how small molecules cause
sedation and paradoxical excitation and may help to accelerate
the pace of CNS drug discovery.
Results
GABAAR ligands produce paradoxical excitation in zebrafish.
To determine how sedatives affect zebrafish behavior, we
assembled a set of 27 CNS depressants in ten functional classes
(Fig. 1a, Supplementary Table 1) and tested these compounds in a
battery of automated behavioral assays. The behavioral assays
were originally devised to discriminate between a broad range of
neuroactive compounds23. Here, the assays were used to profile
anesthetics and other CNS-depressants. In one assay, we used
excitatory violet light stimuli to identify compounds that reduce
motor activity (Fig. 1b, Supplementary Movie 1). In another
assay, we used low-volume acoustic stimuli to identify com-
pounds that enhance startle sensitivity (Fig. 1b, Supplementary
Movie 2). Most CNS depressants caused a dose-dependent
decrease in animals’ average motion index (MI) (Supplementary
Fig. 1), however, we noticed a striking exception.
Two anesthetic GABAAR ligands, etomidate and propofol,
caused enhanced acoustic startle responses (eASRs). These eASRs
occurred in response to a specific low-volume acoustic stimulus,
but not to other stimuli (Fig. 1a, b, Supplementary Figs. 2 and 3).
Unlike vehicle-treated controls, all the animals in a well treated
with etomidate showed robust eASRs (Supplementary Movie 3
and 4). High speed video revealed that the eASRs resembled short
latency C-bends (Fig. 1c). Multiple eASRs could be elicited with
multiple stimuli (Fig. 1d). Etomidate’s half maximal effective
concentration (EC50) for causing eASRs was 1 μM, consistent
with its EC50 against GABAARs in vitro (Fig. 1e)27. Neither
etomidate or propofol was toxic at the concentrations that caused
eASRs (Supplementary Table 2). The eASRs persisted for several
hours and rapidly reversed after drug washout (Fig. 1b, f).
Curiously, not all anesthetics caused eASR behaviors in zebrafish,
including isoflurane (a volatile inhalational anesthetic that is
relatively toxic in zebrafish), dexmedetomidine (a veterinary
anesthetic and alpha-adrenergic agonist), and tricaine (a local
anesthetic and sodium channel blocker) (Fig. 1a). Together, these
data suggest that a subset of GABAAR ligands produce sedation
and paradoxical excitation in zebrafish.
To determine if other GABAAR ligands caused similar
phenotypes, we used the phenoscore metric to quantify
similarities between the archetypal profile caused by etomidate
(6.5 uM) and a diverse range of GABAergic compounds
(Supplementary Table 3). Average phenoscores of DMSO-
treated negative controls were significantly less than etomidate-
treated positive controls (0.2 versus 0.71, P < 10−10,
Kolmogorov–Smirnov test) (Supplementary Fig. 20). Average
phenoscores for the test compounds fell on a continuum between
the positive and negative controls (Fig. 1g). Based on statistical
simulations, these phenoscores were subdivided into three
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categories: weak, intermediate, and strong (Supplementary
Note 1).
Compounds with the strongest phenoscores (0.71 < x < 1)
included several anesthetic and neurosteroid PAMs including
etomidate, propofol, progesterone, and 11-deoxycorticosterone
(DOC) (Fig. 1g). The highest scoring treatments for these
compounds produced behavioral profiles that were both strongly
sedating and produced high-magnitude eASRs (Supplementary
Fig. 2). These profiles were not statistically different from the
positive controls (P > 0.05, Kolmogorov–Smirnov test, Supple-
mentary Fig. 20). Together, these data suggest that a subset of
GABAAR PAMs cause sedation and paradoxical excitation in
zebrafish. However, due to the overlapping pharmacology of
numerous GABAAR subtypes, these data do not clearly point to
any specific subset of receptor subtypes as being necessary or
sufficient for these behaviors.
In humans, the M-current is a low-threshold, non-inactivating,
voltage-dependent current that limits repetitive action potentials
and has been implicated in propofol-induced paradoxical
excitation28,29. To determine if M-currents affect eASRs in
zebrafish, we tested several M-current activators and inhibitors.
In animals treated with M-current activators (flupirtine30,31 and
ICA-06967332), eASR magnitudes significantly decreased (Sup-
plementary Fig. 6, P < 0.01, two-tailed t-test, n= 6 wells; 8 fish/
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well). By contrast, in animals treated with M-current inhibitors
(linopirdine, XE-991, and oxotremorine33) eASR magnitudes
significantly increased (Supplementary Fig. 6, P < 0.000001, two-
tailed t-test, n= 6 wells; 8 fish/well). These data suggest that
zebrafish eASRs are a form of paradoxical excitation affected by
potassium channel M-currents.
Large-scale behavioral screening identifies hit compounds. To
prepare for large-scale screening, we calculated phenoscores for
hundreds of positive and negative control wells (treated with
etomidate or DMSO, respectively). The average phenoscores of
the positive controls were significantly greater than the negative
controls (0.7, ± 0.11 SD versus 0.1 ± 0.05 SD), suggesting that a
large-scale screen would have an expected false positive and
negative rate of 2% and 0.4%, respectively (at a threshold of 3 SD)
(Fig. 2a, Z-factor= 0.7, n= 944 wells).
Then, we screened a library of 9512 structurally-diverse
compounds plus 2336 DMSO-treated negative controls, and
analyzed their effects on sedation and paradoxical excitation.
Visualized as a contour plot, the highest density of phenoscores
occurred in three major regions (Fig. 2b). The first region
contained 11,679 compounds and DMSO-treated control wells
that did not phenocopy etomidate. The second region contained
44 potentially toxic compounds that immobilized zebrafish but
did not cause paradoxical excitation. The third region contained
125 compounds that both produced immobilization and
phenocopied etomidate and were considered primary screening
hits (Supplementary Table 4, Supplementary Fig. 7).
To organize these hit compounds by structural similarity, we
clustered them based on Tanimoto similarities and visualized the
results as a dendrogram that contained 14 clusters (Fig. 2c).
Several clusters included compounds previously associated with
GABAARs (Fig. 2c, d). For example, Cluster 10 included several
dihydro/quinazolinones that are structurally-related to metha-
qualone, a sedative hypnotic drug (Fig. 2c, d). A second cluster,
Cluster 14, included several isoflavonoids, which are structurally-
related to flavonoid sedatives34. Overall, we selected a broad range
of 57 primary hit compounds across all the clusters to re-
purchase and re-test (Supplementary Table 4). Each compound
was re-tested in a dose-response format from 0.1 to 100 µM and
scored based on its ability to immobilize zebrafish and increase
eASRs. Together, 81% of these primary hit compounds (46/57)
caused reproducible eASR phenotypes at one or more concentra-
tions (Fig. 2e, Supplementary Fig. 8, and Supplementary Table 4),
indicating a high rate of reproducibility from the primary screen.
To determine if these compounds targeted human GABAARs,
we tested them in a fluorescent imaging plate reader (FLIPR)
assay on HEK293 cells transfected with α1β2 and α1β2γ2 human
GABAAR subtypes. In this cell line, etomidate, tracazolate, and
propofol increased fluorescence in the presence of GABA, as
expected for GABAAR PAMs. In addition, half of the tested hit
compounds (23/46) also showed PAM activity (Fig. 2f, Supple-
mentary Fig. 9). By contrast, PAM activity was not observed with
negative control compounds including BGC 20-761 (an HTR6
antagonist) and PTX (a GABAAR channel blocker) which likely
reduced GABAAR activity due to inhibition of constitutively
active GABAARs in the system. Interestingly, the PAM activity of
two hit compounds, 7013338 and 5942595, was significantly
greater than the positive controls (Fig. 2f, P < 0.0001, two-tailed t-
test, n= 4). While some of the compounds appeared to function
in this assay as negative allosteric modulators (NAMs), reductions
in fluorescence were likely due to toxicity-induced cell loss
(Fig. 2f, Supplementary Table 5). In addition to the PAM assay,
four hit compounds directly activated GABAARs in the absence of
GABA, including 5860357, 6091285, 5835629, and 7284610
(Supplementary Fig. 9). The strongest direct activator, 5835629,
did not further enhance GABAAR activation in the PAM assay,
presumably because the cells were already maximally activated by
the compound before GABA was added. These data suggest that
behavioral screens in zebrafish can enrich for compounds with
activity at specific human receptors. In addition, these data
suggest that many of the hit compounds identified in the screen
cause sedation and paradoxical excitation via GABAARs.
Hit compounds act on targets including GABAAR and HTR6.
To determine if any of the hit compounds acted on non-GABAAR
targets, we used the Similarity Ensemble Approach (SEA)35 to
predict targets based on ‘guilt-by-association’ enrichment factor
scores (EFs). Among the top-ranked 1000 screening compounds,
150 targets were enriched (Supplementary Table 6). As we ana-
lyzed subsets of hit compounds with increasing phenotypic
stringency, the number of enriched targets decreased (Fig. 3a, b).
The most stringent set of 30 top-ranked hit compounds contained
25 enriched targets including GABAARs, 5α-reductase, mGluRs,
and 5-HTRs (Supplementary Table 7). By contrast, this stringent
set of hit compounds were not enriched for other sporadically
predicted targets such as histone deacetylase, matrix metallo-
proteinase, and carbonic anhydrase (Fig. 3b). As additional
negative controls, we tested 48 reference compounds targeting
receptors with relatively low EF scores and confirmed they did
not cause eASR phenotypes at any concentration (Supplementary
Table 8, Supplementary Fig. 10). Together, these data suggest that
the hit compounds may act on GABAARs, 5α-reductase, mGluRs,
or 5-HTRs (Supplementary Note 2).
A second approach to target identification was to test the
binding affinity of hit compounds against a panel of 43 human
and rodent neurotransmitter-related targets. Of 46 hit com-
pounds, 33 of them bound to at least one of 19 receptors at a Ki <
Fig. 1 GABAAR PAMs enhance acoustic startle in zebrafish. Zebrafish were treated with the indicated compounds and analyzed for changes in behavioral
responses. a The scatter plot quantifies acoustic startle response as a z-score (y-axis) in zebrafish treated with the indicated CNS-depressants (x-axis) at
the indicated concentrations (colorbar). Each point represents the average of n= 12 wells and 6 experimental replicates (also listed in Supplementary
Table 1). b These plots show how the indicated compounds impact zebrafish motor activity (y-axis) over time (x-axis) (n= 12 wells, shaded boundary=
95% confidence interval; nMI, normalized motion index). Colored bars above the x-axis represent the timing and duration of low-volume acoustic stimuli
(gray bars) and violet light stimuli (purple bars). The vertical dotted line indicates where the first assay ends and the second begins. c Representative
images of animals treated with the indicated compounds. Time stamps indicate the time elapsed from the initial presentation of a low-volume acoustic
stimulus. d These plots compare the motor activity (y-axis) over time (x-axis) of animals treated with DMSO (gray) or etomidate (red) (n= 50 larvae).
Consecutive stimuli (n= 60) are indicated by vertical gray bars. e Dose-response curve showing phenoscores at the indicated concentrations (each point
represents n= 12 wells/dose, error bars: ± SD). f Bar plot showing normalized response to the indicated stimulus (tap or violet light) of animals treated
with DMSO, 6 μΜ propofol, or 6 μΜ etomidate (n= 12 wells, error bars: ± SD) for the indicated durations. g Average phenoscores (y-axis) of zebrafish
treated with the indicated compounds. Dashed lines intersecting the y-axis at 0.51 and 0.71 correspond respectively to 1% and 5% significance cutoffs, as
determined from statistical simulations. Compounds are grouped by ligand class: (1) GABABR agonist, (2) GABAAR orthosteric agonist, (3) PAM of δ-
subunit containing GABAARs, (4) GABAAR BZ-site PAM, (5) GABAAR non-BZ-site PAM, (6) GABAAR neurosteroid PAM, (7) GABAAR anesthetic PAM
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10 μM (Fig. 3c, d). Several hit compounds bound to multiple
targets, including compound 7145248, which bound to TSPO, the
benzodiazepine receptor (BZP), dopamine transporter, and the
alpha 2b receptor (Fig. 3d). The most common targets (binding >
5 compounds) included BZP, sigma 2, HTR2A/B/C, HTR6, and
TSPO (Fig. 3c, d). TSPO, previously known as the peripheral
benzodiazepine receptor (PBR) (because it was originally
identified as a binding site for benzodiazepine anxiolytic drugs),
is a mitochondrial protein that supplies cholesterol to steroid-
producing enzymes in the brain36. TSPO ligands are thought to
enhance GABAergic signaling by increasing neurosteroid pro-
duction. However, some TSPO ligands, including
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benzodiazepines and zolpidem, also bind to GABAARs directly37.
We found that 14 hit compounds bound to TSPO in vitro
(Fig. 3c, d), and that two TSPO reference ligands, PK 11195 and
AC 5216, both caused eASRs in vivo (Fig. 3e). Of the 14
compounds that bound to TSPO in vitro, 5 compounds
potentiated GABAAR in FLIPR assays (Fig. 3c; 2f, green
arrowheads). These data suggest that TSPO ligands promote
anesthetic-related phenotypes via direct interactions with
GABAARs, indirect effects on neurosteroidogenesis, or both.
Both target identification approaches, SEA and the in vitro
receptor binding assays, implicated HTR6. For example, SEA
predicted that seven hit compounds, six benzenesulfonamides
and one piperazine, targeted HTR6 (Fig. 4a, Supplementary
Table 9). These compounds reproducibly caused eASRs in vivo
(Fig. 4b). In vitro, six of these hit compounds bound to HTR6 at
nanomolar concentrations (Ki= 54–807 nM) (Fig. 4c). To
determine their functional effects, we tested them for agonist
and antagonist activity in G-protein and β-arrestin pathways at
eight serotonin receptor subtypes (1A, 2A, 2B, 2C, 4, 5A, 6, and
7A). Six of the compounds antagonized HTR6 in vitro. Most of
them antagonized both G-protein and β-arrestin pathways,
suggesting that the compounds were unbiased HTR6 antagonists
(activity range 3.30 nM–18.2 μΜ) (Fig. 4d). By contrast, a
structurally-related piperazine, 5801496, did not cause eASRs
in vivo. To determine if any annotated HTR6 antagonists also
caused eASRs, we analyzed six structurally-diverse HTR6
reference antagonists. Two of these reference antagonists, BGC
20-761 and idalopirdine, reproducibly caused eASRs in vivo
(Fig. 4b). It is unclear why only 2/6 reference HTR6 antagonists
caused eASRs in zebrafish, but it may be related to issues with
absorption, metabolic stability, and/or structural differences
between human and zebrafish receptors. A panel of 36 additional
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5-HT modulating ligands at various serotonergic targets did
not cause eASRs at any concentration tested (Supplementary
Table 9). Together, these data suggest that a subset of HTR6
antagonists cause eASRs in zebrafish.
A neural substrate for paradoxical excitation. To determine
which regions of the brain were active during eASRs, we visua-
lized whole-brain activity patterns by pERK labeling38. In DMSO-
treated control animals, pERK labeling showed broad patterns of
activity in the optic tectum, telencephalon, and other brain
regions (Fig. 5a, b). By contrast, in animals treated with etomidate
or propofol, pERK labeling was broadly reduced (Fig. 5c–e; P <
0.0005, Mann–Whitney U test). Acoustic stimuli significantly
activated a cluster of neurons in the caudal hindbrain at the base
of the 4th ventricle near the auditory brainstem and the nucleus
of the solitary tract (NST)39 at the level of the area postrema
(Fig. 5f, g; P < 0.0005, Mann–Whitney U test)40, suggesting that
this hindbrain neuron cluster represented a specific substrate of
eASR behavior.
To determine if activity in this region specifically occurred
during eASRs, we analyzed pERK labeling in this region during
four other robust motor behaviors. First, in animals stimulated by
optovin (a reversible photoactivatable TRPA1 ligand)24, neuronal
activity increased in many brain regions including the
telencephalon and optic tectum but not in the hindbrain
(Fig. 5j, k). Second, in DMSO-treated control animals stimulated
by light, neuronal activity increased in the telencephalon and
pineal gland but not in the hindbrain (Supplementary Fig. 13a).
Third, in animals stimulated by the GABAAR antagonist
picrotoxin (PTX), neuronal activity increased in the telencepha-
lon but not in the hindbrain (Supplementary Fig. 13b). Finally, in
DMSO-treated animals stimulated by a strong acoustic stimulus
(hard tap), pERK labeling increased in the midbrain but not in
the caudal hindbrain (Supplementary Fig. 13c). Compared to
lower concentrations of etomidate (6 µM), higher concentrations
of etomidate (50 µM) suppressed eASRs and decreased pERK
labeling in the caudal hindbrain (Supplementary Fig. 13d). Like
etomidate, BGC 20-761 reduced neuronal activity throughout
most of the brain and increased activity in the caudal hindbrain
neuron cluster in response to acoustic stimuli (Fig. 5h, i,
Supplementary Note 3). Together, these data suggest that the
labeled neurons in the caudal hindbrain are a specific substrate of
eASR behaviors.
Hit compounds produce distinct side effect profiles. To
prioritize hit compounds for further development, we tested
them for specific side effects. For example, a serious side effect
of etomidate is that it suppresses corticosteroid synthesis due to
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off-target activity on 11β-hydroxylase, the enzyme that syn-
thesizes cortisol in humans and zebrafish. To determine if any
of the hit compounds suffered from similar liabilities, we
measured their effects on cortisol levels. As a positive control,
we used carboetomidate, a close structural analog of etomidate
that was rationally designed to retain etomidate’s activity on
GABAARs, while disrupting its ability to suppress cortisol
synthesis. Both etomidate and carboetomidate immobilized
zebrafish and caused eASRs (Fig. 1g). As expected, etomidate
lowered cortisol levels in zebrafish, whereas carboetomidate did
not, suggesting that these compounds have similar side effects
in humans and zebrafish (Fig. 6a). Next, we tested 12 hit
compounds in the cortisol assay, including eight GABAAR
ligands (found to be positive in the FLIPR assay), one com-
pound predicted to target GABAAR by SEA (5951201), two
HTR6 antagonists (6225936 and 6029941), and one mysterious
compound with no target leads (5736224). None of these
compounds reduced cortisol levels in zebrafish (Fig. 6a),
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indicating that these ligands cause sedation and paradoxical
excitation without suppressing cortisol levels.
To determine if any of the hit compounds may be analgesic, we
used optovin-induced motor activity as a potential analgesia-
related assay. In humans, general anesthetics reduce perceptions
of pain and suffering. Although it is unclear if fish feel pain,
painful stimuli in humans also cause behavioral responses in
zebrafish. For example, activation of the TRPA1 ion channel
causes pain in humans41, and optovin, a photoinducible TRPA1
ligand, induces strong behavioral responses in zebrafish24. As a
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positive control, we found that etomidate suppressed the optovin
response at the same concentrations that caused eASRs (Fig. 6b).
Similarly, we found that two GABAergic hit compounds, 7114005
and 5942595, also blocked optovin-induced motor activity at the
same concentrations that caused eASRs (Fig. 6b). By contrast,
compounds 5658603 and 7013338 did not suppress the optovin
response (Fig. 6b). The HTR6 antagonist BGC 20-761 also
blocked the optovin response (Supplementary Fig. 16), however
serotonergic hit compounds 6225936, 6028165, and 6212662 only
reduced the optovin response at concentrations that also reduced
eASRs (Supplementary Fig. 16). Together, these data suggest that
the mechanisms controlling sedation and eASRs may be separable
from analgesia, and that some eASR-causing compounds may
cause analgesic-related effects in zebrafish.
To determine if eASRs also occur in adult zebrafish, we treated
adult animals with etomidate and the hit compound 7013338, the
most effective hit compound in the FLIPR assays (Fig. 2f). We
found that both of these compounds also worked in adult
animals, reducing the violet light response, while increasing
acoustic startle (Fig. 6c). These data suggest that the mechanisms
underlying eASR phenotypes are not limited to larvae but also
exist in adult zebrafish.
In humans, therapeutic windows for many inhalational
anesthetics are only 2-fold, while therapeutic indices for
intravenous anesthetics are not much better42. Many of the hit
compounds also had relatively narrow efficacy windows (Fig. 6d).
Numerous analogs of key hit compounds including thiophenes,
aryloxycarboxamides, quinazolines, and sulfonamides had lower
activity than the original hits (Supplementary Fig. 17), suggesting
that substantial medicinal chemistry would be needed to increase
the potency of the primary hit compounds.
Compound 7013338 activated human GABAARs more than
any other hit compound in the FLIPR assay (Fig. 2f). However,
its efficacy window was relatively narrow (10–50 µM), raising
questions about its structure activity relationship (SAR)
(Fig. 6e). To analyze its SAR, we generated 21 analogs with
different substituents on the A-, B-, and C-rings (Fig. 2d,
Supplementary Fig. 18, and Supplementary Table 10), and
tested these analogs for biological activity in vivo. The most
active analog, JG-18, increased eASR magnitude and widened
the efficacy window from 1 to 50 μM (Fig. 6e). It had a chloro
substituent on C2’ of the B-ring, an ethyl substituent on C2 of
the C-ring, and C-6 propyl and C7 hydroxyl substituents on the
A-ring (Supplementary Fig. 18). In congruence with previous
SAR analyses of isoflavones34, JG-18 and other analogs with
more lipophilic substituents on position C6 of the A-ring and
position C2 of C-ring exhibited increased biological activity
(Fig. 6e). By contrast, analogs with more dramatic enhance-
ments in steric bulk and lipophilicity at these positions (i.e.,
phenethyl and propyl, respectively) exhibited reduced biologi-
cal activity. Likewise, it was notable that capping the polar C7-
hydroxy group of JG-18 with alkyl and acyl groups tended to
lessen biological activity. Importantly, we found that the B-ring
C2’ chloro substituent was absolutely critical for biological
activity, since analogs without it did not cause eASRs.
Previously, it was reported that analogs with alkoxy or
trifluoromethoxy substituents at multiple positions but espe-
cially at C3’ on the B-ring were high affinity GABAAR binders
in vitro43. Surprisingly, compound JG-17 (with a trifluoro-
methoxy substituent on C3’ of the B-ring, an ethyl substituent
on C2 of C-ring, and C6 propyl and C7 hydroxy substituents on
the A-ring) had no biological activity in vivo (Fig. 6e). It is not
clear why these ligands were not active in zebrafish. Perhaps,
the anomaly could be ascribed to low penetrance in vivo,
receptor subtype selectivity, and/or structural differences
between the human and zebrafish GABAARs. Together, these
data suggest that additional SAR analyses may yield analogs
with greater potency and broader efficacy windows in vivo.
Discussion
These studies show that anesthetics and other GABAAR PAMs
cause sedation and paradoxical excitation in zebrafish, and that
this behavioral model has high predictive and construct validity
for identifying modulators of human GABAARs. Indeed, these
studies may have underestimated the number of hit compounds
that targeted GABAARs for several reasons. One reason is that the
in vitro GABAAR FLIPR assay only tested a very small number of
receptor subtypes and subunit isoforms (α1β2 and α1β2γ2). As a
result, these assays would have missed compounds that acted on
other GABAAR subtypes. A second reason is that some of the hit
compounds may act on zebrafish-specific GABAARs. Finally,
some hit compounds that caused eASRs in zebrafish may need to
be bioactivated in vivo, and would therefore not be be active
in vitro. Therefore, even more of the hit compounds may have
targeted GABAARs.
These studies also suggest that non-GABAAR mechanisms may
also affect paradoxical excitation, including HTR6 antagonism.
For example, we found that HTR6 antagonists produced sedation
and paradoxical excitation in zebrafish (Fig. 4). These HTR6
antagonists likely reduce neuronal excitation via different
mechanisms than GABAAR PAMs. GABAARs are widely dis-
tributed in the CNS, suggesting that GABA ligands likely inhibit
most neurons directly. By contrast, HTR6s are restricted to dis-
crete neuronal populations44, suggesting that their effects are
likely propagated through indirect signaling networks. HTR6
antagonists can reduce 5-HT neuronal firing45, presumably by
blocking positive feedback46 control of raphe neurons that
broadly project throughout the brain and spinal cord21.
Researchers have made remarkable progress applying the prin-
ciples of systems pharmacology to structure-based target pre-
dictions47, computer assisted design of multi-target ligands48–50,
and the large-scale prediction of beneficial drug
combinations10,51. Although we focused on predicting targets of
compounds one at a time, in future studies it may be possible to
calculate multi-target enrichment factors among the hit com-
pounds from large-scale phenocopy screens and identify multi-
target mechanisms.
Fig. 6 Hit compounds show diverse efficacy windows and side effect profiles. a This bar plot shows cortisol levels (y-axis) in animals treated with the
indicated compounds (x-axis) including FLIPR-positive GABAergics (green), SEA predicted GABAergics (magenta), serotonergics (blue), and a compound
with undetermined targets (gray) (n= 2–5 experiments, 15 animals/experiment, error bars: ± SEM). b This bar plot shows the normalized responses (y-
axis) of animals treated with the indicated compounds (x-axis) in the pain-related optovin-response suppression assay. c This bar plot shows the
magnitude of behavioral responses of adult zebrafish (y-axis) treated with with the indicated compounds (x-axis). d Dot plot showing efficacy windows for
the indicated compounds with strong (green) or weak (gray) phenocopy scores. Marker size represents the magnitude of the eASR response (n= 12 wells/
condition). Compounds with broad efficacy windows have large green dots at multiple concentrations (x-axis). e This strip plot shows the normalized
acoustic startle response (y-axis) of larvae treated with increasing concentrations (colorbar) of multiple analogs of the screening hit 7013338 (x-axis) (n=
4–6 wells/condition, 8 fish/well)
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The HTR6 antagonists identified in this study add to a growing
body of evidence implicating various serotonin ligands and
receptors in phenotypes related to neuronal inhibition and exci-
tation. Our finding that HTR6 antagonists activate a region in the
zebrafish NST (Fig. 5h, i), are consistent with previous work
showing that HTR6 antagonists activate neurons in the mam-
malian NST46. In rodents, HTR6 antagonists promote sleep47,
reduce anxiety48, and show anticonvulsant properties49. However,
it is not clear if HTR6 causes these effects via specific neuronal
circuits, or more generally by coordinating nervous system tone
and arousal. Furthermore, there are substantial differences in the
central nervous system distribution and pharmacology of the
mouse, rat, and human HTR6 receptors50. So, although HTR6
antagonists phenocopied etomidate in zebrafish, these effects may
not translate to anesthetic activity in humans. Despite promising
effects in rodents, several HTR6 antagonists failed in clinical trials
as cognitive enhancers for the treatment of Alzheimer’s disease51,
underscoring the caveats of generalizing between humans and
model organisms.
These data suggest at least two possible models by which
GABAAR PAMs could cause paradoxical excitation of the
acoustic startle response. One possibility is that the ligands dis-
inhibit the acoustic startle neurons. Alternatively, the ligands may
excite specific neurons directly, due to conditions that reverse the
chloride equilibrium potential, such as the tonic activation of
GABAARs52. Our observation that caudal hindbrain neurons
were activated by acoustic stimuli in etomidate-treated zebrafish
is not the first to link GABA signaling to auditory excitation. For
example, in rodents, gaboxadol activates extrasynaptic GABAARs,
hyperpolarizes resting membrane potential, and converts neurons
in the auditory thalamus to burst mode53. In addition, etomidate
causes purposeless muscle excitement that is exacerbated by
acoustic stimuli in dogs54. In zebrafish, researchers have found
that the offset of optogenetic-induced inhibition of caudal hind-
brain neurons triggers swim responses55. In addition, zebrafish
caudal hindbrain neurons have been shown to be activated during
hunting behaviors, a behavior that requires strong inhibitory
control56. However, exactly how these neurons impact motor
activity, and why startle neurons remain active despite elevated
inhibitory tone, remains unclear.
Although these studies show that GABAAR PAMs cause
paradoxical excitation, pharmacological experiments to deter-
mine which GABAAR subtypes caused eASRs were ultimately
inconclusive. While the majority of GABAARs in the CNS are
benzodiazepine-sensitive γ-containing subtypes, and multiple
benzodiazepines did not cause strong eASRs (Fig. 1g), γ-
containing subtypes may still be very important for eASRs. One
reason is that the benzodiazepines tested in this study only
represent a very small subset of benzodiazepine analogs. Another
reason is that diazepam produced intermediate eASR phenotypes
(Fig. 1g, Supplementary Fig. 2), suggesting that other benzodia-
zepines may cause even stronger eASR phenotypes. Although
etomidate, propofol, neurosteroids, and other anesthetics are
PAMs at δ-subunit containing GABAAR subtypes, these ligands
also modulate γ-containing subtypes. Furthermore, although
THIP and DS2 are reported to have preferential activity at δ-
containing GABAARs, these compounds also modulate γ-
containing receptors57, and they did not cause eASRs. One
alternative explanation is that β-isoforms58,59 could drive the
presence or absence of eASRs. Another possible explanation is
that whereas PAMs may produce immobilizing effects effects via
some receptor subtypes, they may produce eASRs via other
subtypes. In summary, although a subset of GABAAR PAMs
caused eASRs, these compounds may do so via a variety of
receptor subtypes. In future studies, it would be interesting to test
additional benzodiazepines for such effects including midazolam,
which causes paradoxical excitation in humans60. The specificity
of currently available pharmacological tools may be insufficient to
determine which GABAAR subtypes produce eASRs. Therefore,
future studies may require targeted knockouts and other genetic
tools to help identify the key receptor subtypes.
While these studies focused on behavioral profiling, other types
of phenotypic profiling data may further improve the accuracy of
neuroactive compound classification, including whole-brain
imaging. Whole-brain imaging allows researchers to record
real-time firing patterns will likely add massive amounts data to
the behavioral pharmacology field61,62. For example, recent
advances in high-throughput brain activity mapping for systems
neuropharmacology illustrate how whole-brain activity mapping
can be used in primary screening for compounds that activate
specific circuits, or allow researchers to discriminate between
compounds with similar behavioral phenotypes but that work on
different neuronal populations62. These approaches enable pri-
mary screening for compounds that activate specific circuits and
allow researchers to discriminate between compounds with
similar behavioral phenotypes but that work on different neuro-
nal populations.
In summary, we have shown that GABAAR PAMs cause
sedation and paradoxical excitation in zebrafish. Whereas pre-
vious behavior-based chemical screens in zebrafish have identified
neuroactive compounds related to behaviors including sleep25,
antipsychotics23, learning26, and appetite63, we show here that
behavioral profiling can also be used to rapidly identify com-
pounds related to sedation and paradoxical excitation. Future
studies will likely expand the utility of behavior-based chemical
phenocopy screens to additional kinds of neuroactive ligands,
targets, and pathways.
Methods
Fish maintenance, breeding, and compound treatments. We collected a large
number of fertilized eggs (up to 10,000 embryos per day) from group matings of
wild-type zebrafish (from Singapore). All embryos were raised on a 14/10-hour
light/dark cycle at 28 °C until 7 dpf. Larvae were distributed 8 animals per well into
square 96-well plates (GE Healthcare Life Sciences) with 300 µL of egg water.
Compound stock solutions were applied directly to the egg water and larvae were
incubated at room temp for 1 h before behavioral analysis. To determine the
impact of group size on this assay, we analyzed eASR behaviors from animals in
different group sizes (1, 2, 4, 8, 12, 16, 32 animals per well). Although animals in all
groups responded similarly to the stimulus (Supplementary Movie 5), the largest
differences between treated and controls were seen in groups of 8 and 16 animals
(Supplementary Fig. 19). We, therefore, used 8 animals to balance small group size
with a strong MI signal. All zebrafish procedures were and approved by the UCSF’s
Institutional Animal Care Use Committee (IACUC), and in accordance with the
Guide to Care and Use of Laboratory Animals (National Institutes of Health 1996)
and conducted according to established protocols that complied with ethical reg-
ulations for animal testing and research.
Compounds and chemical libraries. All chemical libraries were dissolved in
DMSO. The Chembridge library (Chembridge Corporation) contains 10,000
compounds at 1 mM. The Prestwick library (Prestwick Chemical) contains 1280
approved drugs at 10 mM. All compounds were diluted in E3 buffer and screened
at 10 µM final concentration in < 1% DMSO. Controls were treated with an equal
volume of DMSO. Compounds were validated in 3-12 replicate wells, on 3 replicate
plates. For dose-response behavioral assays, compounds were tested at 7 con-
centrations that ranged from 0.1 to 100 µM, unless otherwise indicated.
Automated behavioral phenotyping assays. Digital video was captured at 25
frames per second using an AVT Pike digital camera (Allied Vision). Each assay
duration was 30–120 s, and consisted of a combination of acoustic and light sti-
muli23. Low (70 db) and high (100 db) amplitude acoustic stimuli were delivered
using push-style solenoids (12 V) to tap a custom built acrylic stage where the 96-
well plate was placed. Acoustic stimuli were recorded using a contact microphone
(Aquarian Audio Products, model# H2a) and the freeware audio recording software
Audacity (http://www.audacityteam.org). Digital acoustic stimulus was generated
as a 70 ms sine wave at various frequencies using Audacity. A computer was used
to playback the audio stimulus as an mp3 using an APA150 150W powered
amplifier (Dayton Audio) played through surface transducers adhered to the
acrylic stage. Stimulus volume was measured using a BAFX 3608 digital sound level
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meter (BAFX Products). Light stimuli were delivered using high intensity LEDs
(LEDENGIN) at violet (400 nm, 11 μW/mm2), blue (560 nm, 18 µW/mm2), and
red (650 nm, 11 μW/mm2) wavelengths. Stimuli and digital recordings were
applied to the entire 96-well plate simultaneously. Instrument control and data
acquisition were performed using custom scripts written in MATLAB and Python.
The zebrafish motion index (MI) was calculated as follows: MI= sum(abs(framen –
framen−1)). Normalized MI (nMI) was calculated as follows: nMI= (MI-min(MI))/
max(MI). Startle magnitude was calculated using numerical integration via the
trapezoidal method (Matlab function trapz) of MI values during stimulus.
Computing the phenoscore. To quantify distances between multi-dimensional
behavioral profiles, we first defined a prototypic behavioral profile to compare
everything else against. Etomidate’s prototypical behavioral profile was determined
from 36 replicates wells treated with etomidate (6.25 μM) on 3 different plates (12
replicates per plate). Using a simulated annealing procedure (described in the
supplement) we identified 12 replicate profiles with the most consistent eASR
response that was also most distant from the control (DMSO) wells. The reference
profile was the average of these 12 profiles. Phenoscore distances were computed
between each well and the reference profile by calculating the correlation distance
(using the correlation distance module from the scipy package in python). The
correlation distance (phenoscore) has a range from −1 to +1. Positive and negative
values represent positive and negative correlation, respectively. Negative values
represent anti-correlation. Experimentally, phenoscores tended to saturate at
around 0.7, a value that represents substantial positive correlation given that the MI
time series is a large vector with >10,000 values. Although etomidate and propofol
are both anesthetic GABAAR PAMs with similar behavioral profiles in zebrafish,
etomidate is more soluble than propofol, so we used etomidate as the archetypal
positive control.
Ranking the screening hits. Phenoscores were computed to assign each com-
pound in the screening library a rank order. Hit compounds were defined as the
top 125 scoring compounds from this ranked list
Calculating response magnitude Z-scores. Response magnitudes were calculated
by averaging the maximum motion index value during 3 repeated violet stimuli or
6 repeated acoustic stimuli. These Motion index magnitudes were converted to Z-
scores using the following equation: Z-score= (magnitude − mean)/SD. Z-scores
were then normalized from 0-1 using the scikit function sklearn.preprocessing.
normalize written for python.
In vitro receptor profiling. In vitro binding assays and Ki data were generated by
the National Institute of Mental Health’s Psychoactive Drug Screening Program
(PDSP), contract no. HHSN-271-2008-00025-C (NIMH PDSP), for assay details:
http://pdsp.med.unc.edu/PDSP%20Protocols%20II%202013-03-28.pdf. Normal-
ized Ki (npKi) values were generated as follows: npKi= 4+ (−log10 (Ki))64.
FLIPR. We used the FLIPR system (Molecular Devices) to quantify GABA-evoked
activity of human GABAARs. We chose a membrane potential dye (Molecular
Devices) to measure changes in membrane potentials and stably transfected
HEK293 cells that expressed α1, β2 and γ2. Since we observed an increase in GABA-
evoked responses when transfected with γ2 transiently, we describe the cells as
having a low level of γ-subunit expression, indicating heterogeneity of GABAAR
compositions in the cell (α1β2 or α1β2γ2). To assay for direct agonists, fluorescence
was subtracted pre- and post compound addition. To assay for PAMs, cells were
treated with compound at 20 uM and then with 5 uM GABA.
Whole-brain activity mapping. Following behavioral experiments, animals were
immediately fixed in 4% paraformaldehyde in PBS and incubated overnight at 4 °C.
Larvae were then washed in PBS+ 0.25% Triton-X (PBT), incubated for 15 min at
70 °C in 150 mM Tris-HCl, pH9, washed in PBT, pearmeablized in 0.05% Trypsin-
EDTA for 30-45 min on ice and washed with PBT. Animals were then blocked for
1 h at room temperature (PBT, 1% bovine serum albumin, 2% normal goat serum,
1% DMSO, and 0.02% sodium azide)38. The following primary antibodies were
diluted into blocking buffer and incubated overnight at 4 °C: α-5HT (1:500,
ImmunoStar), α-tERK (1:750, Cell Signaling), α-pERK (1:750, Cell Signaling).
Secondary fluorescent antibodies (Life Technologies) were used at 1:500 and
incubated in blocking buffer overnight at 4 °C in the dark. Whole-mount fluor-
escent images were obtained using a Leica SP8 confocal microscope. Image pro-
cessing was performed in imageJ. Image registration was performed using the
Computational Morphometry Toolkit (https://www.nitrc.org/projects/cmtk) and a
user interface with the command string defined by Owen Randlett (-awr 010203 -T
8 -X 52 -C 8 -G 80 -R 3 -A ‘--accuracy 0.4’ -W ‘--accuracy 1.6’). Multiple brains
from each condition were then averaged using Matlab scripts to obtain a repre-
sentative neural activity image. Brightness and contrast were adjusted using Fiji
(imageJ). MAP-map calculations (whole-brain ΔpERK significance heat maps)
were performed using the analysis code for MAP-map which can be downloaded
from the website (http://engertlab.fas.harvard.edu/Z-Brain/).
Cortisol detection assay. Cortisol levels were measured in zebrafish65. Briefly, 15,
7-day old larvae were treated with the indicated compounds for 1 h. Larvae were
anesthetized in ice-cold egg water and then snap-froze in an ethanol/dry ice bath.
Larvae were then homogenized in 100 μL of water. Cortisol was extracted from the
homogenate with 1 mL of ethyl acetate, the resulting supernatant was collected and
the solvent allowed to evaporate. Cortisol was dissolved in 0.2% bovine serum
albumin (A7030, Sigma) and frozen at −20 °C. For cortisol ELISA experiments, 96-
well plates (VWR International) were treated with cortisol antibody (P01-92-94M-
P, EastCoast Bio; 1.6 g/mL in PBS) for 16 h at 4 °C, washed, and blocked with 0.1%
BSA in PBS. Cortisol samples and cortisol-HRP (P91-92-91H, EastCoast Bio) were
incubated at room temperature for 2 h and washed extensively with PBS containing
0.05% Tween-20 (Invitrogen). Detection of HRP was performed using tetra-
methylbenzidine (TMB: 22166-1, Biomol) and Tetrabutylammonium borohydride
(TBABH: 230170-10 G, Sigma). Reaction was stopped using 1 M H2SO4. Absor-
bance was read at 450 nm in an ELISA plate reader (SpectraMax MS, Molecular
Devices).
Software. Data acquisition and analysis were carried out using custom scripts in
Matlab (MathWorks) and Python. Figures were prepared using Matlab, Python,
ImageJ (NIH), Prism (GraphPad), and Adobe Illustrator.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The source data for all Figures and Supplementary Figs. in the current study are available
in the Zenodo repository: https://doi.org/10.5281/zenodo.3336616
Code availability
Scripts used for data acquisition and analysis are available from the corresponding author
upon reasonable request. For Enrichment Factor calculations, code is available upon
request.
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